



NDA 050705/S-028

SUPPLEMENT APPROVAL

sanofi-aventis U.S. LLC
c/o Sanofi US Services Inc.
Attention: Stephen Canning
Manager, Global Regulatory Affairs
450 Water Street
Cambridge, MA 02141

Dear Stephen Canning:

Please refer to your supplemental new drug application (sNDA) dated and received March 17, 2025, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Rifater (rifampin, isoniazid, and pyrazinamide USP) tablets.

This “Prior Approval” supplemental new drug application provides for revisions to the Rifater Prescribing Information (PI): in the **WARNINGS** section a statement that cases of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported with components of Rifater was added.

The **PRECAUTIONS** section, under the subsection ‘Carcinogenesis, Mutagenesis, Impairment for Fertility’ for the individual components (rifampin, isoniazid, and pyrazinamide) of Rifater were revised and the subheadings ‘Rifampin’ and ‘Isoniazid’, and the subheading ‘Pyrazinamide’, were also modified.

Additionally, revisions were made to separate the subsections ‘Pregnancy - Teratogenic Effects’ into two subsections, one for Rifater and one for individual components (Rifampin, Isoniazid, and Pyrazinamide) of Rifater. Under the subheading ‘Isoniazid,’ added that there are no available data indicating an increased risk of miscarriage or other adverse maternal or fetal outcomes with the use of isoniazid for the treatment of TB during pregnancy.

Under the **ADVERSE REACTIONS** section, subsection Pyrazinamide, added a new subheading ‘Hypersensitivity,’ and added SJS, TEN, DRESS and AGEF as well as relocated additional symptoms related to hypersensitivity from ‘Miscellaneous’ subheading to the ‘Hypersensitivity’ subheading.

Additionally, minor editorial revisions were made throughout the PI.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, email Lori Kolejian, MS, MSAMB, Regulatory Project Manager, at Lori.kolejian@fda.hhs.gov, or call (301) 796-0881.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Office of New Drugs
Center of Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
10/08/2025 02:59:56 PM